This bill seeks to significantly improve Medicare beneficiaries' access to cutting-edge medical technologies. It achieves this by amending the Social Security Act to allow for the conditional approval of certain innovative devices under the Medicare New Technology Add-On Payment (NTAP) Program. This change is designed to ensure that medical breakthroughs can be provided to beneficiaries more swiftly, avoiding unnecessary delays in adoption. Specifically, a "breakthrough device" — defined as one designated for expedited FDA review and subsequently approved for that indication — may receive conditional NTAP approval. This conditional approval is granted even if the device has not received full FDA clearance by the standard application deadline, as long as the clearance occurs before July 1 of the relevant fiscal year. The bill mandates that this provision be implemented in a budget-neutral manner and applies to breakthrough devices approved on or after July 1, 2023.